Fig. 2: HAT1-knockout-mediated resistance leads to the long-term survival of melanoma cells treated with BRAF inhibitor. | Oncogenesis

Fig. 2: HAT1-knockout-mediated resistance leads to the long-term survival of melanoma cells treated with BRAF inhibitor.

From: Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R

Fig. 2

a Immunoblotting for the indicated proteins in A375 and SKMEL-28 HAT1-knockout (HAT1-KO) cells. b Clonogenic assay results for A375 and SKMEL-28 cells, expressing non-targeting (NT) or HAT1 sgRNAs, in the presence of vemurafenib (3 μM) (left). Colony number for the data are shown (right). c Clonogenic assay results for A375 and SKMEL-28 cells, expressing NT or HAT1 sgRNAs, in the presence of dabrafenib (100 nM) (left). Colony number for the data presented (right). Data are presented as the mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, calculated using Student’s t test.

Back to article page